Evidence map›Paper›PMID 32485996›Full record

ReviewPharmaceuticals (Basel, Switzerland)2020

Novel 1,2,4-Oxadiazole Derivatives in Drug Discovery.

Karol Biernacki, Mateusz Daśko, Olga Ciupak, Konrad Kubiński, Janusz Rachon, Sebastian Demkowicz

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Biochemistry and biophysics reports · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Karol BiernackiDepartment of Organic Chemistry, Faculty of Chemistry, Gdansk University of Technology,Narutowicza 11/12, 80-233 Gdansk, Poland.ORCID 0000-0003-3036-8693
Mateusz DaśkoDepartment of Inorganic Chemistry, Faculty of Chemistry, Gdansk University of Technology,Narutowicza 11/12, 80-233 Gdansk, Poland.ORCID 0000-0002-3367-6491
Olga CiupakDepartment of Organic Chemistry, Faculty of Chemistry, Gdansk University of Technology,Narutowicza 11/12, 80-233 Gdansk, Poland.
Konrad KubińskiDepartment of Molecular Biology, Faculty of Biotechnology and Environment Sciences,The John Paul II Catholic University of Lublin, Konstantynów 1i, 20-708 Lublin, Poland.ORCID 0000-0001-6870-845X
Janusz RachonDepartment of Organic Chemistry, Faculty of Chemistry, Gdansk University of Technology,Narutowicza 11/12, 80-233 Gdansk, Poland.
Sebastian DemkowiczDepartment of Organic Chemistry, Faculty of Chemistry, Gdansk University of Technology,Narutowicza 11/12, 80-233 Gdansk, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Five-membered 1,2,4-oxadiazole heterocyclic ring has received considerable attentionbecause of its unique bioisosteric properties and an unusually wide spectrum of biological activities.Thus, it is a perfect framework for the novel drug development. After a century since the1,2,4-oxadiazole have been discovered, the uncommon potential attracted medicinal chemists'attention, leading to the discovery of a few presently accessible drugs containing 1,2,4-oxadiazoleunit. It is worth noting that the interest in a 1,2,4-oxadiazoles' biological application has been doubledin the last fifteen years. Herein, after a concise historical introduction, we present a comprehensiveoverview of the recent achievements in the synthesis of 1,2,4-oxadiazole-based compounds and themajor advances in their biological applications in the period of the last five years as well as briefremarks on prospects for further development.

Indexed as

1,2,4-oxadiazoledrug designdrug discoverymedicinal applicationstructure-activity relationshipsynthetic methods

Identifiers

PMID32485996
PMCPMC7345688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.